Vaxart, Inc. announced the appointment of Edward B. Berg as the Company's first in-house General Counsel and Senior Vice President, effective February 14, 2022. Mr. Berg has practiced law for more than 30 years and has represented Fortune 500 and mid-cap companies in biotechnology, pharmaceuticals and life sciences. He joins Vaxart from BioMarin Pharmaceutical Inc., where he served as VP, Deputy General Counsel since 2018.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.861 USD | -4.27% | -8.32% | +53.46% |
05-13 | Transcript : Vaxart, Inc., Q1 2024 Earnings Call, May 13, 2024 | |
05-13 | Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.46% | 159M | |
+12.22% | 116B | |
+12.79% | 106B | |
-9.32% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-15.09% | 16.33B | |
+6.16% | 14.14B | |
+29.51% | 12.02B |
- Stock Market
- Equities
- VXRT Stock
- News Vaxart, Inc.
- Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel